Preliminary results from HERKULES-1: a phase 1b/2, open-label, multi-center study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors

被引：0
|
作者：
Wang, J. [1 ]
Johnson, M. [2 ]
Barve, M. [3 ]
Pelster, M. [2 ]
Chen, X. [4 ]
Li, Z. [4 ]
Gordon, J. [4 ]
Reiss, M. [4 ]
Pai, S. [4 ]
Falchook, G. [5 ]
Tolcher, A. [6 ]
机构：
[1] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Tennessee Oncol Drug Dev Unit, Nashville, TN USA
[3] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[4] Erasca Inc, San Diego, CA USA
[5] Sarah Cannon Res Inst HealthONE, Drug Dev Unit, Denver, CO USA
[6] NEXT Oncol, Oncol, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [21] Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
    Migden, Michael R.
    Chai-Ho, Wanxing
    Daniels, Gregory A.
    Medina, Theresa
    Wise-Draper, Trisha M.
    Kheterpal, Meenal
    Tang, Jennifer C.
    Ibrahim, Sherrif F.
    Bolotin, Diana
    Verschraegen, Claire
    Zeitouni, Nathalie C.
    Tsai, Katy K.
    Donthireddy, Laxminarasimha
    Bommareddy, Praveen K.
    Hou, Jeannie W.
    Hong, Walter
    Davar, Diwakar
    CANCER RESEARCH, 2024, 84 (07)
  • [22] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [23] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
    Bendell, Johanna
    Fuchs, Charles
    Voss, Martin
    Bauer, Todd M.
    Choueiri, Toni K.
    Drilon, Alexander
    Thorn, Katharine
    Wijayawardana, Sameera
    Moser, Brian
    Urunuela, Arantxa
    Wacheck, Volker
    Harding, James J.
    CANCER RESEARCH, 2017, 77
  • [24] ARTACUS: AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES
    Luke, Jason
    Migden, Michael
    Chai-Ho, Wanxing
    Bolotin, Diana
    Wise-Draper, Trisha
    Poklepovic, Andrew
    Laux, Douglas
    Kheterpal, Meenal
    Verschraegen, Claire
    Collichio, Frances
    Lutzky, Jose
    Daniels, Gregory
    Tsai, Katy
    Navia, Susan
    Castro, Henry
    Bommareddy, Praveen
    Pirzkall, Andrea
    Coffin, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A580 - A580
  • [25] Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    McKean, Meredith
    Aggen, David Henry
    Lakhani, Nehal J.
    Bashir, Babar
    Luke, Jason J.
    Hoffman-Censits, Jean H.
    Alhalabi, Omar
    Bowman, Isaac Alex
    Guancial, Elizabeth A.
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Kacena, Katherine
    Malek, Karim S.
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study
    Warren, Julia T.
    Walkovich, Kelly J.
    Bolyard, Audrey Anna
    Dickerson, Kathryn E.
    Walter, Jolan E.
    Cadavid, Diego
    Chapa, Eloisa
    Chen, Kelly
    MacLeod, Richard
    Peters, Katie
    Polisson, Richard
    Dale, David C.
    BLOOD, 2022, 140 : 1408 - 1410
  • [27] Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
    Westin, Shannon N.
    Fu, Siqing
    Tsimberidou, Apostolia
    Piha-Paul, Sarina
    Akhmedzhanov, Fechukwu
    Yilmaz, Bulent
    McQuinn, Lacey
    Brink, Amanda L.
    Gong, Jing
    Leung, Cheuk Hong
    Lin, Heather
    Hong, David S.
    Pant, Shubham
    Carter, Brett
    Jazaeri, Amir
    Gershenson, David
    Sood, Anil K.
    Coleman, Robert L.
    Shah, Jatin
    Meric-Bernstam, Funda
    Naing, Aung
    GYNECOLOGIC ONCOLOGY, 2023, 168 : 76 - 82
  • [28] IGNYTE: AN OPEN-LABEL, MULTICENTER, PHASE 1/2 (PH 1/2) CLINICAL TRIAL OF RP1 ± NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Middleton, Mark
    Milhem, Mohammed
    Aroldi, Francesca
    Sacco, Joseph
    VanderWalde, Ari
    Baum, Scott
    Samson, Adel
    Chesney, Jason
    Niu, Jiaxin
    Rhodes, Terence
    Bowles, Tawnya
    Emamekhoo, Hamid
    Tsai, Katy
    In, Gino
    Beasley, Georgia
    Chmielowski, Bartosz
    Dalac-Rat, Sophie
    Kahler, Katharina
    Munoz, Eva
    Olsson-Brown, Anna
    Bommareddy, Praveen
    Menezes, Lavita
    Pirzkall, Andrea
    Coffin, Robert
    Harrington, Kevin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A538 - A538
  • [29] Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
    Kyaw Zin Thein
    Sarina A. Piha-Paul
    Apostolia Tsimberidou
    Daniel D. Karp
    Filip Janku
    Abdulrazzak Zarifa
    Jatin Shah
    Denái R. Milton
    Stacie Bean
    Lacey McQuinn
    Jing Gong
    Rivka Colen
    Brett W. Carter
    Vivek Subbiah
    Deby C. Ogbonna
    Shubham Pant
    Funda Meric-Bernstam
    Aung Naing
    Investigational New Drugs, 2021, 39 : 1357 - 1365
  • [30] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
12345